Innate immune signaling drives late cardiac toxicity following DNA-damaging cancer therapies
Journal of Experimental Medicine · 06.03.2023 · 220 (3)
DOI: 10.1084/jem.20220809 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, online erschienen am 19.12.2022. Verfasst von Achraf Shamseddine und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Translational Oncology, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Hauptthemen laut MEDLINE: Cardiotoxicity, Neoplasms, DNA Damage, Antineoplastic Agents. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, Department of Defense.
Abstract (Originalsprache)
Late cardiac toxicity is a potentially lethal complication of cancer therapy, yet the pathogenic mechanism remains largely unknown, and few treatment options exist. Here we report DNA-damaging agents such as radiation and anthracycline chemotherapies inducing delayed cardiac inflammation following therapy due to activation of cGAS- and STING-dependent type I interferon signaling. Genetic ablation of cGAS–STING signaling in mice inhibits DNA damage–induced cardiac inflammation, rescues late cardiac functional decline, and prevents death from cardiac events. Treatment with a STING antagonist suppresses cardiac interferon signaling following DNA-damaging therapies and effectively mitigates cardiac toxicity. These results identify a therapeutically targetable, pathogenic mechanism for one of the most vexing treatment-related toxicities in cancer survivors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Translational Oncology, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Radiation Oncology, Mary Bird Perkins Cancer Center, Baton Rouge, LA, USA.
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Clinical Chemistry Service, Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
ORCID-Profile: Achraf Shamseddine, Suchit H Patel, Valery Chavez, Zachary R Moore, Mutayyaba Adnan, Melody Di Bona, Jun Li, Chau T Dang, Lakshmi V Ramanathan, Kevin C Oeffinger, Jennifer E Liu, Richard M Steingart, Alessandra Piersigilli, Nicholas D Socci, Angel T Chan, Anthony F Yu, Samuel F Bakhoum, Adam M Schmitt
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- Department of Defense
- National Institutes of Health
- Memorial Sloan-Kettering Cancer Center
Zitieren
APA
Shamseddine, A., Patel, S. H., Chavez, V., Moore, Z. R., Adnan, M., Di Bona, M., Li, J., Dang, C. T., Ramanathan, L. V., Oeffinger, K. C., Liu, J. E., Steingart, R. M., Piersigilli, A., Socci, N. D., Chan, A. T., Yu, A. F., Bakhoum, S. F., & Schmitt, A. M. (2023). Innate immune signaling drives late cardiac toxicity following DNA-damaging cancer therapies. Journal of Experimental Medicine, 220(3). https://doi.org/10.1084/jem.20220809
Vancouver
Shamseddine A, Patel SH, Chavez V, Moore ZR, Adnan M, Di Bona M, et al. Innate immune signaling drives late cardiac toxicity following DNA-damaging cancer therapies. Journal of Experimental Medicine. 2023;220(3). doi:10.1084/jem.20220809
BibTeX
@article{Shamseddine2023,
author = {Shamseddine, Achraf and Patel, Suchit H and Chavez, Valery and Moore, Zachary R and Adnan, Mutayyaba and Di Bona, Melody and Li, Jun and Dang, Chau T and Ramanathan, Lakshmi V and Oeffinger, Kevin C and Liu, Jennifer E and Steingart, Richard M and Piersigilli, Alessandra and Socci, Nicholas D and Chan, Angel T and Yu, Anthony F and Bakhoum, Samuel F and Schmitt, Adam M},
title = {Innate immune signaling drives late cardiac toxicity following DNA-damaging cancer therapies},
journal = {Journal of Experimental Medicine},
year = {2023},
volume = {220},
number = {3},
doi = {10.1084/jem.20220809}
}
EUVIMED